Waning mRNA Vaccine Effectiveness—Boosters as Absolute Must According to Latest Study

In what appears to be the largest study of its kind recently Texas Biomedical Research Institute in San Antonio and the University of Verona in Italy announced the tracking of waning antibodies against SARS-CoV-2, the virus behind COVID-19, by gender, age and time. Led by physician and investigator Dr. Brandon Michael Henry as well as a postdoc researcher the team of prominent researchers at University of Verona evaluated patient antibody levels prior to and after the second doses of the COVID-19 vaccine.  They conducted an analysis after one, two and six months of the last jab. Overall Dr. Henry reports by month six all study subjects experienced at least a 50% reduction in lifesaving antibodies.  But not everyone fares the same. For whatever reason women have more COVID-19 fighting antibodies than men, regardless of age. Overall Dr. Henry reports women “have slightly better immune responses.” TrialSite notes another point of view however—the current batch of early-stage, version 1.0 vaccine products on the one hand help alleviate short-term crises including greater hospitalization and death caused by SARS-CoV-2. However, on the other hand they are not products that sto...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee